JNJ-77242113
janssen
['frontier 1', 'psoriasis', 'jnj-77242113', 'sonnet']
congress #wcd2023singapore | robert bissonnette presents efficacy &amp; safety results of frontier 1 study, a phase ii, randomized, placebo-controlled, dose-ranging study of oral jnj-77242113, an il-23r antagonist peptide, in moderate-to-severe plaque #psoriasis. at w16, 
The Psoriasis and Psoriatic Arthritis Hub is an open-access online resource that provides balanced and up-to-date medical education. #Psoriasis #RheumTwitter